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Abstract
The Angiopoietin-1/Tie2 signalling pathway is important in regulating vascular function. 
Angiopoietin-1 (Ang1Angpt1) induced Tie2 activation promotes vascular endothelial cell 
survival and reduces vascular leakage. Angiopoietin-2 (Ang2Angpt2), a weak agonist/n 
antagonist of Tie2, opposes and regulates Ang1Angpt1 action. The Tie family of receptor 
tyrosine kinases, Tie2 and Tie1, exist as either homo-or heterodimers. The molecular 
complex between the receptors are also crucial in controlling Ang1Angpt1 signalling, hence 
the molecular balance between Ang1Angpt1:Ang2Angpt2 and Tie2:Tie1 is important in 
determining endothelial integrity and vascular stability. This review presents evidence of the 
change observed in the Angiopoietin /Tie molecules in various pathophysiological conditions 
and discusses the potential clinical applications of these molecules in vascular complications.  
Keywords: Angiopoietin; Tie receptor; Endothelial; Vascular disease
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Introduction
Angiopoietins (Angpt) are group of growth factors that are involved in regulating vascular 
function [1]. The group was earlier compriseds of four members, Ang1Angpt1-4, however 
currently the family only consists of Angpt1, Angpt2 and Angpt4. Angpt3 is locus to mouse 
and does not exert significant biological effects on human endothelial cells  [2-5]. The 
Angiopoietin ligands bind to Tie2, which together with Tie1, make up the Tie family of 
receptor tyrosine kinases [6]. Ang1Angpt1 and Ang2Angpt2 are two main members that have 
been well characterised and while Ang1Angpt1 can acts as a protective ligand that stimulates 
Tie2, Ang2Angpt2 is capable of exerting an partial agonistic/antagonist effect [3]. 
The balance between the levels of Ang1Angpt1 and Ang2Angpt2, in part, determines the 
integrity of blood vessels. Changes in the molecular ratio of both these ligands are associated 
with various pathophysiological conditions including tumour angiogenesis, sepsis and 
cardiovascular disease [7-96-8]. The levels of the Tie receptors are also altered in various 
disease states, which can lead to changes in the magnitude of Angptiopoietin 1 signalling. 
Alongside the therapeutic benefits of targeting this pathway, this review explores the 
potential application of the AngAngpt/Tie system as biomarkers in predicting vascular 
disease. 
 Angiopoietin 1 & 2
Angiopoietins are oligomeric glycoproteins that share a similar overall structure. They consist 
of an N-terminal super-clustering domain (SCD), a central coiled-coil domain (CCD) that 
allows for homo-oligomerisation of the ligand, a linker region, and a C-terminal fibrinogen-
related domain (FReD). The FReD domain is further composed of three regions, A, B and P 
[109]. Angpt1 predominantly acts on endothelial cells, inducing various vascular shaping 
functions. The functional roles of Angpt1 arise from the binding of the ligand, in tetramer 
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form or higher, to the Tie2 homodimer complex [14, 1511,12]. On binding, the tyrosine 
kinase domain (Figure 1) autophosphorylates thereby initiating a cascade of downstream 
signals as shown in Figure 21.  The integrity and survival of the vasculature arises from the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway, subsequent of Tie2 phosphorylation. 
Recruitment of the regulatory p85 subunit of PI3K to the receptor induces activation of the 
PI3K/AKT pathway. Upon activation of AKT, this function serves to inhibit forkhead 
transcription factor FKHR. FKHR propagates endothelial cell apoptosis, therefore inhibition 
of this factor serves to function in the cell survival [11-13, 17-1913-18]. Additionally, the 
PI3K pathway can also induce vessel remodelling and enlargement through the activation of 
nitric oxide synthase (eNOS) via the ShcA adaptor protein, as well as activation of focal 
adhesion kinase (FAK). Endothelial cell migration stems from the recruitment of 
Downstream of Kinase R (Dok-R) to the receptor [2019]. Phosphorylation of this protein 
creates an interacting site for Nck and p21 activating kinase (PAK1) to which cell migration 
occurs, furthermore, PAK1 has been reported to have other cellular functions like 
cytoskeletal remodelling [1620, 21]. The Angpt1 signalling also plays a role in inflammation, 
specifically an anti-inflammatory role. A20-binding inhibitor of NF-B activatiuon (ABIN-2) 
is recruited to the tyrosine kinase domain whereby this causes inhibition of IKK’s and 
subsequently suppresses transcription factor NF-κB 70 [22-24].Angiopoietin 1 (Ang1) 
predominantly acts on endothelial cells as a protective ligand in  aiding vascular survival and 
acts as an anti-apoptotic agent [10-12].
Angiopoietin 1 exerts its protective effect by binding to Tie2 receptors [13]. For Ang-1 to 
activate the receptor, monomers of the ligand assemble as a tetramers or high order multimers 
and bind to Tie2/Tie2 homodimers [14]. On binding, the tyrosine kinase domain in the 
intracellular region of the Tie2 homodimer complex autophosphorylates initiating a cascade 
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of downstream signals as shown in Figure 1. Growth factor receptor-bound protein 2 (GBR2) 
is one of the adaptor protein that recruits to activated Tie2 and goes on to phosphorylate 
extracellular regulated-kinase (ERK 1/2), which is responsible for endothelial cell survival 
and migration [15]. Angiopoietin 1 exerts its anti-apoptotic effect by activating the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway [12,16]. This is facilitated by recruitment 
of the regulatory p85 subunit of PI3K to activated tyrosine kinase domain of Tie2 [17,18].  
Ang1 also regulates migration in endothelial cells via adaptor protein Dok-R recruiting to the 
active Tie2 receptor [19]. In addition, Ang1 promotes recruitment of A20-binding inhibitor of 
NF-κB activation (ABIN-2) to Tie2, which inhibits IKKs and subsequently suppresses NF-
κB 70, a transcription factor involved in inflammation [20-22].
While Angpt1 maintains endothelial cell quiescence and stability during development, it’s 
protective effect on the mature vasculature is predominately observed during a disease state 
[25].  Jeansson et al (2011) showed that Angpt1 knock out mice displayed profound organ 
damage during injury or microvascular stress. Diabetic Angpt1 knock out mice also displayed 
increased mesangial matrix expansion and sclerosis compared to diabetic control mice, 
suggesting Angpt 1 to be more effective under disease conditions [25].  
Whilst the most commonly studied function of Ang1Angpt1-Tie2 signalling is vascular 
protection, this particular pathway also has a role in reducing monocyte/macrophage 
infiltration, by depleting adhesion molecules available on endothelial cells that allow for 
leukocyte adhesion [2326].
Angptiopoietin 2 shares approximately 604% amino acid homology with Ang1Angpt1. The 
main structural difference between the two is within the variable P domain that forms the 
receptor binding region of this ligand [3]. Angiopoietin 2 (Ang2Angpt2 ) binds with Tie2 and 
interacts with the Ig2 domain of the receptor. While Tie2 forms many interdomain 
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interactions with Ang2Angpt2, the binding of this ligand does not cause any conformational 
changes in the kinase domain of the receptor [109]. The antagonistic effect of Ang2Angpt2 
has been shown to inhibit Ang1Angpt1 signalling and suppress vascular quiescence and 
stability, however there have been evidence to show Ang2Angpt2 at high concentrations 
actactings as an partial agonist in the absence of Ang1Angpt1 [24, 25, Korhonen et al 
201626-2827-30]. The nature of the opposing action of Ang2Angpt2 depends on the 
pathogenic condition and forkhead box 01 (FOXO1) levels inof the blood vessel [27527-
28,30]. The antagonist effect of Angiopoietin pt2 was observed in mice infected with 
Mycoplasma pulmonis, that led to suppressed Tie2 phosphorylation and increased FOXO1 
activation. In contrast, mice under pathogen-free conditions, Angpt2 promoted Tie2 
activation, suppressed FOX01 and maintained vascular integrity7. In addition, the different 
vascular environment may determine Angpt2 fate as an agonist or antagonist based on the 
levels of vascular endothelial protein tyrosine phosphatase (VEPTP) [29ref, Souma et al 
2018]. The ability of Angpt2 to activate Tie2 is due to the low levels of VEPTP present in 
lymphatic vasculature. Inhibiting levels of VEPTP increase Angpt2 induced phospho-AKT 
activity in human umbilical vein endothelial cells (HUVEC) [ref, Souma et al 201829]. At 
times of endothelial remodelling, Ang2Angpt2 is regarded as an inhibitor of vascular 
quiescence and stability.  
 Tie receptors
Tunica Interna Endothelial (Tie) receptor are a group of Receptor Tyrosine Kinases (RTKs) 
consisting of two isoformsgenes, Tie1 and Tie2. Both receptors are very similar in structure, 
with 76 % similar homology between them [26,2730, 3131-32]. As shown in Figure 2, the 
extracellular region of both the receptors consist of two amino-terminal immunoglobulin (Ig) 
domains, three epidermal growth factor (EGF) repeats, a third Ig domain and three 
fibronectin type-III repeats [30, 3226,2831-33]. The receptor spans through the membrane 
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and the tyrosine kinase domain is found in the intra cellular region towards the carboxyl-
terminal [26,2830,3231-32]. The binding region for Ang1Angpt1 on Tie2 is the protruding Ig 
domain and EGF repeats [3329]. As discussed, Tie2 is the main receptor for AngAngpt 1 
signalling. For a tetramer or higher order Ang1Angpt1 to activate Tie2, homodimerisation of 
the receptor is required via the formation of an intermolecular β- sheet between the third 
fibronectin type III repeat [34]. 
Tie1 is an orphan receptor and its involvement in Angiopoietin signalling is still unclear 
[65]unable to respond to Ang1Angpt1 [5]. The Tie 1 receptor can form heterodimers with 
Tie2 and has shown to regulate suppress Ang1Angpt1 signalling [350]. The inability for 
Ang1Angpt1 to bind to heterodimer Tie2/Tie1 receptors suppresses its signalling capacity 
(Figure 2).  While Tie2/Tie2 homodimers promote stabilisation of vessels via Ang1Angpt1, 
the increase in the pool of Tie2/Tie1 promotes Ang2Angpt2 binding to these heterodimer 
receptors causing vascular regression and sprouting [361]. Interestingly, Korhonen et al 
(2016) have reported that Angpt1 induced Tie2 activation and hence vascular response is 
significantly reduced in Tie1 deficient mice.  In addition, Tie1 also capable of undergoing 
proteolytic cleavage of its ectodomain. This cleavage inherently upregulates 
Ang1Angpt1/Tie2 signalling by means of increasing the Tie2:Tie1 ratio [372].
 Angiopoietin-Tie signalling in vascular disease
Angiopoietin/Tie axis and mediators of atherosclerosis 
Coronary artery disease is developed through the formation of fatty plaqgues by the process 
called atherosclerosis. During atherosclerosis increased pro-inflammatory cytokine activity at 
the sub- endothelial layer compromises the integrity of the vessel, and allows the recruitment 
of macrophages which alongside fatty acids contribute to the developing plaqgue [383].  
Tumour Necrosis Factor α (TNFα) is an important pro-inflammatory mediator produced by 
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macrophages/monocytes during atherosclerosis. TNFα causes a time-dependent increase in 
the Tie2:Tie1 ratio by enhancing Tie2 and suppressing Tie1 expression in cultured 
endothelial cells [394]. Additionally, TNFα has also been shown to induce proteolytic 
cleavage of the Tie1 ectodomain, in endothelial cells [28]. In contrast, Vascular endothelial 
growth factor (VEGF), a multifunctional cytokine that has also shown to promote 
atherosclerosis [354140], decreases the Tie2:Tie1 ratio by shedding the Tie2 extracellular 
domain [34,3640, 4239,41-42]. This regulatory control of the Tie receptor levels by various 
cytokines can influence Angiopoietin Angpt1 signalling and effect vascular function in a 
disease state. Further evidence of changes in the Tie2:Tie1 ratio has been reported in patients 
with cardiovascular risk factors including obesity and dyslipidaemia. These patients display 
increased plasma circulated sTie2, a soluble form of the Tie2 receptor [4337]. This is 
important to note as sTie2 is referred to a ligand trap which will allow for binding with 
Ang1Angpt1, therefore reducing the availability of Ang1Angpt1 for binding with the Tie2 
homodimer, consequently resulting in decreased signalling activity [4438].
Disturbed blood flow in the vasculature is another component that promotes endothelial 
inflammation and is associated with atherosclerosis [4539]. A particular study has suggested 
Nnon-laminar flow has shown to induce Tie1 expression at sites of atheroma in mice models 
[460]. In contrasct, normal laminal flow in endothelial cell cultures, downregulates Tie1 
expression. Decrease in Tie1 expression in apoE-deficient mice have also displayed a dose-
dependent reduction in atherosclerotic lesions in the distal aorta, highlighting the importance 
of Tie1 in atheroma development [460].
The levels of Angiopoietins hashave also been shown to be affected in diseased blood vessels 
[41-4447-50]. Atheroma plaqgues with high microvascular density, display high levels of 
Ang2Angpt2 and consequently lead to a fall in the Ang1Angpt1:Ang2Angpt2 ratio [471]. 
Further reports have shown the use of anti-Ang2Angpt2 antibodies in reducing the size of 
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fatty streak formation in carotid artery plaqgues in mice [482]. In myocardial ischemic mice 
induced by left coronary artery ligation, an increase level of Ang2Angpt2 and a reciprocal 
decrease in Ang1Angpt1 has also been reported [493]. In ApoE-/- mice a significant increase 
in Ang2Angpt2 secretion from atherosclerotic lesions has also been reported [5044]. This 
increase of Ang2Angpt2 hastens vascular inflammation by activating NF-κB-dependent 
proinflammatory cascades in end thelial cells, thus increasing the migration of macrophages 
into the atherosclerotic lesions. Ang2Angpt2-/- in these mice have further demonstrated slow 
progression and reduce instability of the plaque [5044]. 
Angiopoietin/Tie axis and Diabetes 
Inflammation is the main cause of vascular complications including retinopathy, nephropathy 
and peripheral vascular disease in patients with diabetes [4551]. Ang2Angpt2, a marker of 
vascular instability under inflammatory conditions [30], has been reported to be increased in 
patients with Type 2 diabetes [5246]. Animal studies have supported this association by 
showing an upregulation of Ang2Angpt2, and reduction in Ang1Angpt1 ligand in 
cerebrovascular of diabetic mice causing diminished function in the ischemic brain [5347]. 
High levels ofElevated Angpt2 hasis also been linked to pericyte dropout in diabetic 
retinopathy [48,4954, 55]. Transgenic expression of Ang2Angpt2, displays pericyte dropout 
in animals, a similar phenomenon observed in early diabetic retinopathy. Interestingly, 
injection of Ang1Angpt1 has been shown to suppress retinopathy and retinal oedema in 
diabetic mice [560]. 
The physiological level of the Tie2 receptor has also been reported to change in diabetic mice 
[571]. Db/db mice subjected to myocardial ischemia display significant reduction in Tie2 and 
impair Ang1Angpt1 induced Tie2 signalling. On the contrary, there is evidence to show that 
elevated glucose concentrations reducesreduce the activity of Tie2 without reducing 
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expression or increasing internalisation of the receptor [582]. In cultured macro- and 
microvascular human endothelial cells, elevated glucose has shown to suppress 
Ang1Angpt1/Tie2 signal transduction [582].  In both human microvascular coronary 
endothelial cells (HMCEC) and human umbilical vein endothelial cells (HUVEC), elevated 
glucose showed inhibition of Ang1Angpt1 mediated Tie2 and PI3K/AKT phosphorylation 
without effecting the expression f the receptor [582]. This data suggests that elevated 
glucose interrupts the vasoprotective effect of Ang1Angpt1 in endothelial cells which may 
contribute to vascular diseases associated with Diabetes.   
Angiopoietin/Tie axis and Sepsis
Sepsis is identified as having augmented inflammation as well as widespread endothelial 
dysfunction, which results in a vast increase in vascular permeability and disease. The most 
well know link between sepsis and the Angpt/Tie2 axis is the increase of Angiopoietin 
Angpt2, and hence changes in the Ang1Angpt1:Ang2Angpt2 ratio [87, 593-6155]. Patients’ 
with severe sepsis have beenare reported to have significantly increased levels of serum 
Ang2Angpt2, compared to normal individuals. This increase in Ang2Angpt2 positively 
correlates with pro-inflammatory cytokines, TNF-α and Interetrleukin-6 (IL-6), in these 
patients [6256]. Overexpression of Ang2Angpt2 in mice can lead to sepsis associated 
hemodynamic alterations including systemic hypotension and pericyte dropout. These 
changes observed in mice have been shown to reverse by intravenous injections of 
Ang1Angpt1 [878]. This highlights the importance of the balance between the two ligands, in 
the role of normal vascular functionThis highlights again how important the balance is 
required between the Angiopoietin ligands in normal vascular function. In addition, a drug 
repurposing study found that 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins) 
have the potential to inhibit Ang2Angpt2 and improve conditions of sepsis in 
patientsproduction in endothelial cells. Albeit the clinical improvements were seen to be non-
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significant, the authors suggest measurements of Angpt2 levels could be useful as a 
biomarker for future clinical trials with statins [6357]. 
Angiopoietin/Tie axis as a therapeutic targets of vascular disease
Due to the protective nature Ang1Angpt1 has on the vasculature, huge interest has bebeen 
focused in the area of Ang1Angpt1 mimetics to improve vascular function in various diseases 
[5864-671].  Increase in permeability of the blood-brain barrier after stroke is associated with 
increase in the molecular ratio between Ang2Angpt2:Ang1Angpt1 [682]. Ang1Angpt1 and 
the more potent recombinant proteinform, COMP-Ang1Angpt1, both have are both able to 
reduce the permeability of the blood-brain barrier in mice  . Recombinant Ang1Angpt1 has 
also been shown to inhibit VEGF- induced vascular permeability after ischeamicischaemic 
stroke and improve neurological function in mice [6470]. In diabetic nephropathy, the 
increased levels of Ang2Angpt2 areis associated with glomerulus endothelial dysfunction 
[7165]. COMP-Ang1Angpt1 has been shown to improve glomerulus function by suppressing 
urinary microalbuminuria in diabetic mice models [660]. The application of an Ang1Angpt1 
mimetic, has also been shown in to reduce microvascular leakage and airway obstruction in 
Asthma [671]. In mice modelsa mouse model of airway hyperresponsiveness, COMP-
Ang1Angpt1 reduced inflammatory migration of eosinophils into the lung airways and 
improved airway function [671]. 
Another approach to improve vascular stability is to target levels of Ang2Angpt2. Two 
different methods have been reported to block the activity of Ang2Angpt2.  These include the 
use of monoclonal antibodies [66-6872-74] and high-affinity nuclease resistant RNA ligands 
[7569,760]. Monoclonal antibodies targeting Ang2Angpt2 haves been widely used in 
inhibiting tumour angiogenesis [7266,7367]. MEDI3617, an Ang2Angpt2 specific 
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monoclonal antibody, has been shown to block Ang2Angpt2 expression in mice and inhibit 
metastasis tumour growth of a non-small cell carcinoma of the lung [7266]. This particular 
antibody has also been seen to inhibit metastasis of lung and lymph nodes [77]. Targeting 
Ang2Angpt2 by means of using specific nuclease-resistant RNA aptamer have been shown to 
suppress tumour angiogenesis [7569] and inhibit corneal neovascularisation in mice [760]. 
Recent, advances in the area of ligand trap peptides to inhibit Ang2Angpt2 signalling is also 
being explored in stabilising and imp oving blood vessel function [781]. 
Angiopoietin/Tie axis as potential biomarker of vascular disease
Besides having its therapeutic advantages, the levels of Angiopoietin ligands have also been 
investigated as potential biomarkers in various diseases [72,7379, 80]. In patients with severe 
sepsis, plasma levels of Ang1Angpt1 and Ang2Angpt2 have been analysed for diagnosticses 
purposes [792]. In these patientspatients’, low levels of Angiopoietin1 Angpt1 were found to 
be a significant predictor of 28 day28-day mortality.  High Angiopoietin Angpt2 levels in 
patients with sepsis, showed correlations with a substantial risk of morbidity during ICU 
admissions. Furthermore, high Ang2Angpt2 also correlated with organ dysfunction. 
Survivors of sepsis on the other hand displayed a high Ang1Angpt1:Ang2Angpt2 ratio.  This 
evidence gives insight into the usefulness of angiopoietin as a clinical biomarker of disease 
severity and patient outcome during sepsis. 
Circulated Circulating levels of Ang2Angpt2 haves also been reported as an independent 
predictor of major adverse cardiovascular events in chronic kidney disease patients [8174]. 
The study also found a significant correlation between Ang2Angpt2 and all-cause of 
mortality in patients with chronic kidney disease. Ang2Angpt2 is also elevated in patients 
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after undergoingafter cardiac surgery [7582]. The observed increase in Angpt2 is linked with 
post-surgery respiratory failure.This increased observed is linked with respiratory failure 
post-surgery.  A recent study has recorded Recently, elevated levels of Ang2Angpt2 have 
been recorded in patients with acute lung injury, which exerts moderate effects on 
microvascular function and promotes immune cell infiltration of the vasculature [7380]. 
Prospective use of Ang2Angpt2 level as an additional tool for cardiovascular disease risk 
assessment in patients with both hyperglycaemia and hypertension has also been recently 
investigated [8376]. 
Even though there hashave not been much clinical studies supporting the Tie receptor as a 
diagnostic markers, the ability of various inflammatory cytokines including TNF-α, VEGF 
[3440] and Interleukin-1 (IL-1) [7784] to influence the levels of Tie1 and Tie2, makes 
profiling of these receptors an attractive way in predicting vascular disease. The only 
limitation in this is accessing intact endothelial cells directly from patients for analysis. There 
have been some studies that have isolateding endothelial cells from patients for molecular 
analysis [78-8085-87]. Single Cell reverse transcription PCR has been used to analyse gene 
expression of vascular inflammatory mediators RACE and MCP-1 in endothelial cells 
isolated from patients with type 2 diabetes [7986]. Quantitative immunofluorescence has also 
been successfully applied on endothelial cells isolated from biopsy to determine expression 
levels of vascular proteins [8087]. 
We have modified the technique illustrated by Yu et al. [8578] in isolating intact endothelial 
cells from coronary catheters that have been used on patients undergoing percutaneous 
coronary intervention [881]. With this technique we are currently profiling Tie1, Tie2 and 
Ang2Angpt2 levels to the pathophysiological condition of the patient to help in further 
understanding the relevance of the Ang1Angpt1 signalling pathway in vascular disease. 
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Conclusion
A range of evidence exists showing changes in the molecular levels of Ang1Angpt1, 
Ang2Angpt2 and their Tie receptors associated with various disease states.  Understanding 
the normal molecular balance and the extent to which abnormal levels lead to vascular 
problems could potentially be used for early diagnostic purposes. Currently, there has been 
great focus on Ang1Angpt1 mimetics, Angpt2 inhibiting antibodies and peptibodies, as 
therapeutic agents to improve and enhance Tie2 signalling in disease. Future research in 
patient profiling of biomarkers will complement the area of Angiopoietin signalling in 
clinical applications.  
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Figure Legends 
Figure 1. Angpt1-Tie2 signalling pathway 
Schematic representation of Angpt1 induced Tie2 signalling pathway in endothelial cells. 
Key downstream signalling molecules activated on Angpt1 induced Tie2 activation include: 
Docking protein R (Dok-R); A20 binding inhibitor of NFkB (ABIN-2); and 
Phosphatidylinositol 3-kinase (PI3K). Angpt1 exerts its effect to induce vascular stability, 
vessel remodelling and enlargement, migration and anti-inflammation. 
Figure 2. Structure of Tie receptors  
The extracellular domain of the receptors consists of Ig domains; EGF and fibronectin type 
III repeats. The intracellular part of the receptors consists of the tyrosine kinase domain. Tie2 
can form homodimers (Tie2/Tie2) or heterodimers when partnered with Tie1 (Tie2/Tie1).  
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Figure 1. Angpt1-Tie2 signalling pathway 
Schematic representation of Angpt1 induced Tie2 signalling pathway in endothelial cells. Key downstream 
signalling molecules activated on Angpt1 induced Tie2 activation include: Docking protein R (Dok-R); A20 
binding inhibitor of NFkB (ABIN-2); and Phosphatidylinositol 3-kinase (PI3K). Angpt1 exerts its effect to 
induce vascular stability, vessel remodelling and enlargement, migration and anti-inflammation. 
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Figure 2. Structure of Tie receptors   
The extracellular domain of the receptors consists of Ig domains; EGF and fibronectin type III repeats. The 
intracellular part of the receptors consists of the tyrosine kinase domain. Tie2 can form homodimers 
(Tie2/Tie2) or heterodimers when partnered with Tie1 (Tie2/Tie1). 
109x60mm (300 x 300 DPI) 
Page 30 of 33
URL: http:/mc.manuscriptcentral.com/lrst
Journal of Receptors and Signal Transduction
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
The Angiopoietin ligands and Tie receptors: Potential diagnostic biomarkers of vascular disease
Addressed Reviewer’s comments:
Thank you for reviewing the manuscript titled ‘The Angiopoietin ligands and Tie receptors: Potential 
diagnostic biomarkers of vascular disease’ and providing your valuable input. The comments have 
been taken on board and manuscript amended, as shown by track changes, accordingly. For each 
comment the changes incorporated to the paper are shown below: 
Reviewer: 1
Comments to the Author
The review captures some essential concepts of the Angiopoietin (Angpt)-Tie system based on 
relevant literature. Especially, the authors propose a concept that the ratios of Angpt1/Angpt2 and 
Tie2/Tie1 determine signaling outcomes in endothelial cells. Whereas decreased Angpt1/Angpt2 
ratio is shown in numerous studies (and diseases) both in mice and human patients to be correlated 
with worse disease outcome, the significance of the Tie2/Tie1 ratio is less well understood. The 
authors’ conclusion is based on in vitro work conducted in cultured endothelial cells, whereas more 
recent mouse studies suggest alternative concepts. Thus, in light of newer data, including gene 
targeted mouse models, the authors should provide a more comprehensive view of the following 
aspects of Angpt-Tie signaling: 
Major comments:
1. The authors focus on vascular protective functions of Angpt1 (e.g. Page 3, row 50, 55). 
However, Angpt1 gene deletion did not have a major effect in baseline conditions in the mature 
vasculature in adult mice (Jeansson, JCI, 2012), thus, the protective function of Angpt1 is especially 
relevant in disease conditions. The authors should, therefore, define the context when referring to 
various Ang1 functions, which, in addition to vascular integrity, also include vessel remodeling and 
vessel enlargement, as well as endothelial cell migration and anti-inflammation (as also shown in Fig 
1.
Thank you for highlighting that the protective function of Angpt1 is relevant in disease conditions. 
Key findings from Jeansson et al 2012 have now been included in the manuscript on page 5. In 
addition, have included an extensive overview of the different Angpt1 signalling molecules and their 
function from page 4-5. This is also reflected in Figure 1.
2. Reference 24 (Page 4, row 55) shows that Angpt2 acts as a partial agonist/antagonist of Tie2 
in vitro. However, it has been shown that Angpt2 acts as a Tie2 agonist in the lymphatic vasculature 
(e.g Gale et al, 2002 and Souma et al., 2018). In addition, Kim et al. (ref. 25) and Korhonen et al (ref 
missing, JCI, 2016) showed that Angpt2 acts as a Tie2 agonist in vivo in basal conditions, but the 
agonist activity of Angpt2 is lost in inflammation, switching Angpt2 into an antagonist. To provide a 
more comprehensive view of Angpt2 function, the authors should discuss these in vivo data, and 
also modify the last sentence of Figure 1 legend.
I agree with the comment made here regarding the ability of Angpt2 to act as agonist in lymphatic 
and vasculature system and so to support this a more comprehensive review of the function Angpt2 
has now be included with key findings from Souma et al 2018, Kim et al and Korhonen et al 2016 
discussed on page 6.
3. Page 5, row 35 and Figure 2. The authors propose a concept that Angpt1 signals mainly via 
Tie2 homodimers, whereas Tie2-Tie1 heterodimers favor Angpt2 signaling (based on in vitro data in 
refs 30 and 31). However, it has been recently shown (Korhonen et al., JCI, 2016) that Angpt1 and 
Angpt2-induced vascular responses (e.g. enlargement of tracheal vessels) do not occur in Tie1-
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The Angiopoietin ligands and Tie receptors: Potential diagnostic biomarkers of vascular disease
deficient mice. In addition, Angpt1-induced Tie2 phoshorylation and FOXO1 inactivation were 
significantly decreased in Tie1 deficient mice. Thus, the data suggested that Tie1 promotes Angpt1-
induced vascular responses. It was also demonstrated that Angpt1 induced direct molecular 
interactions between Tie1 and Tie2 in endothelial cell cultures. Thus, the authors should discuss 
alternative models based on what is described above, and modify the last sentence of Fig. 2 legend.
Thank you for your comment. We have discussed the evidence to support the involvement of Tie1 
receptor in promoting Angpt1 vascular response and have included this on page 7. In line to this 
information we have modified Figure 2 and it’s corresponding legend by removing that Angpt 1 is 
only capable of signalling through Tie2 homodimer. 
4. Abstract. Page 2, row 14. Angiopoietin-2 is referred to as “an antagonist of Tie2”. This 
indeed, is the cased in many, but not all cellular models. E.g. Angpt2 has been reported to function 
as a Tie2 agonist in vivo e.g. in the lymphatic vasculature. Thus, more appropriate would be to use 
“weak agonist/antagonist”.
I agree with the comments made by the reviewer and we have changed the abstract to reflect this.
5. Introduction. Page 3, row 9.  “The group comprises of four members, Ang1-4”. Does this 
refer to the old nomenclature, where mouse Ang3 corresponded to human Ang4? Currently, 
angiopoietins are referred to as Angpt1, Angpt2 and Angpt4 (see Lee et al, Faseb J, 2004: “Although 
the percent amino acid identity between Ang3 and Ang4 is much less than other human and mouse 
counterparts, their chromosomal localizations indicate that the Ang3 locus in mouse is indeed 
syntenic to the Ang4 locus in humans.”). 
Thank you for this comment. We have now changed the old nomenclature to the new one and have 
referred the angiopoietins to consist of Angpt1, 2 and 4 (Page3). We have adapted the new 
nomenclature throughout the manuscript. 
6. Introduction. Page 3, row 50. Please spell out abbreviations when first introduced in the 
text, and use abbreviations thereafter. The official nomenclature (Angpt) should be introduced to 
the reader, even if the authors wish to use the old nomenclature.
Thank you for this observation. All text has been now spelled out before abbreviating. The official 
nomenclature Angpt has now been introduced throughout the manuscript. 
 
7. Legend for the last Figure was missing. The proposed “increase in Tie1” is not well justified, 
especially since Tie1 cleavage during inflammation and infection has been found to lead to loss of 
Tie1 in the vascular endothelium (Kim et al., Korhonen et al, JCI, 2016). 
This is a valid point and we have decided to remove this graphical figure from our submission. 
Minor comments:
8. Introduction. Page 3, row 21. “The balance between the levels of Ang1 and Ang2 determines 
the integrity of blood vessels.” Please add “in part”, to indicate that The Angpts are one of the 
regulators of vessel integrity.
9. Page 4, paragraph starting on row 29 is short, and should be combined with another 
paragraph. 
10. Page 4, row 39. Please indicate if the homology refers to amino acid level homology.
11. Page 5, row 9. Replace “isoforms” by “genes”.
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12. Page 5, row 25. Is “homodimerization” correct, since Angpt1 needs to be at least a tetramer 
in order to activate Tie2? Ref. is also missing here.
13. Page 6, row 10. Note that TNF-alfa also induces Tie1 ectodomain cleavage in vivo (Korhonen 
et al, JCI, 2016).
14. Page 8, row 41. Ref 57 shows a correlation between statin use and improved condition in 
sepsis in a retrospective study, whereas a case-control study of critically ill subjects demonstrated 
decreased Angpt2 levels among other markers, but not improved condition of the patients.
15. Page 9, row 40: was metastasis studied in ref 66?
16. Conclusions. Row 34. Note that in addition to Ang1 mimetics, Angpt2 blocking antibodies 
and peptibodies have been widely investigated.
17. References. Please use uniform style for references, including journal abbreviations (refs 4, 
9, 10, 25, 26, 50, 52, 57, 73, 77, 80)
18. Modify the text accordingly.
a. Page 6, row 41: “Non-laminar flow has been shown to…mouse models”. Next sentence: 
“downregulates”.
b. Page 7, row 38: “High levels of Ang2 have also been linked..”
c. Page 8, row 26: “Patients…”
d. Page 8, row 32: ”…Interleukin-6…”
e. Page 8, row 39: The sentence staring “This highlights..” requires modification.
f. Page 8, row 51: “… as a therapeutic target…”
g. Page 8, row 60: “Ang1 and the more potent recombinant protein, COMP-Ang1 are both able 
to reduce…”
h. Page 9, row 8: “… the increased levels…are associated...”
i. Page 9, row 9: “COMP-Ang1 has been shown…”
j. Page 9, row 15: The sentence starting “The application..” needs reformatting.
k. Page 9, row 17: “ In a mouse model of…”
l. Page 9, row 33: “…targeting Ang2 have...”
m. Page 9, row 35: “…antibody, has been shown to...”
n. Page 9, row 40: “…have been shown to…”
o. Page 9, row 59: “…for diagnostic purposes…”
p. Page 10, row 10: “…correlated with organ…”
q. Page 10, row 18: “Circulating levels of Ang2 have…”
r. Page 10, row 25: use either after or undergoing 
s. Page 10, rows 25-32: The sentences starting “This increased..” and “Recently, elevated…” 
need reformatting.
t. Page 10, row 53: “…isolated..”
u. Page 20, Figure 1 legend: “…inhibiting inflammation..”
We have gone through all the minor comments and have made the suggested changes as highlighted 
in the manuscript.  Once again we would like to thank the reviewer for providing their expert advice 
and we hope that the amendments address the concerns  highlighted above.  
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